Single-site, Open-label, Randomized, Cross-over Study in Healthy Japanese Subjects to Evaluate the Bioequivalence of Single Dose Rotigotine Transdermal Patch (2 mg/24 h) Comparing 2 Different Formulations
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2014
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors UCB Pharma Inc
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Jul 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
- 27 Jun 2012 Planned end date changed from 1 Jun 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.